Chronic environmental arsenic poisoning

International Journal of Dermatology

Volumn 38, Issue 6, 1999, Pages 401-410

  Piamphongsant, Thada ^a  

^a Institute of Dermatology Thailand   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOLEVULINIC ACID; ARSENIC; DIMERCAPROL; ENVIRONMENTAL POISON; ETRETINATE; PENICILLAMINE; SUCCIMER;

BOWEN DISEASE; BOWENOID PAPULOSIS; HUMAN; HYPERKERATOSIS; INTOXICATION; INTRAMUSCULAR DRUG ADMINISTRATION; KERATOSIS PALMOPLANTARIS; REVIEW; SIDE EFFECT; SKIN DISEASE; TREATMENT OUTCOME; WATER CONTAMINATION;

ARSENIC POISONING; CHRONIC DISEASE; DEVELOPING COUNTRIES; HUMANS; POISONING; SKIN DISEASES; THAILAND; WATER POLLUTION, CHEMICAL;

EID: 0033058297     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1999.00555.x     Document Type: Review

References (90)

1. Chakraborty AK, Saha KP. Arsenic dermatosis from tube well water in west Bengal. Indian J Med Res 1987; 85: 326-334.
2. Das D, Mandal B, Chowdhury PP, et al. Arsenic contamination in ground water in six districts of west Bengal, India: the highest calamity in the world. Part I. Analyst 1995; 120: 643-650.
3. Chatterjee A, Das D, Mandal B, et al. Arsenic contamination in ground water in six districts of west Bengal, India: the biggest calamity in the world. Part II. Analyst 1995; 120: 917-924.
4. Yeh S. Skin cancer in chronic arsenism. Hum Pathol 1973; 4: 469-485.
5. Yu HS, Sheu HM, Ko SS, et al. Studies on black foot disease and chronic arsenism in southern Taiwan: with special reference to skin lesions and fluorescent substances. J Dermatol 1984; 11: 361-370.
6. Chen CJ, Chuang YC, You SL, et al. A retrospective study on malignant neoplasms of bladder, lung and liver in black foot disease endemic area in Taiwan. Br J Cancer 1986; 53: 399-405.
7. Chen CJ, Chuang YC, Lin TM, et al. Malignant neoplasms among residents of a black foot disease -endemic area in Taiwan: high arsenic artesian well water and cancers. Cancer Res 1985; 45: 5895-5899.
8. Borgono JM, Vincent P, Venturino H, et al. Arsenic in the drinking water of the city of Antofagasta: epidemiologic and clinical study before and after the installation of a treatment plant. Environ Health Perspect 1997; 19: 103-105.
9. Hopenhayn-Rich C, Biggs ML, Fuchs A, et al. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology 1996; 7: 117-124.
10. Cebrine ME, Albores A, Aguilar M, et al. Chronic arsenic poisoning in the north of Mexico. Hum Toxicol 1983; 2: 121-133.
11. Hotta N. Arsenic Contamination in Asia. Miyazaki, Japan: Asia Arsenic Network, 1995.
12. Hotta N. Arsenic Contamination in Ground Water in Bangladesh. Miyazaki, Japan: Asia Arsenic Network, 1997; 2: 2-6.
13. Huang YZ, Qian XC, Wang GQ, et al. Syndrome of endemic arsenism and fluorosis. A clinical study. Chin Med J (Engl) 1992; 105: 586-590.
14. Feinglass EJ. Arsenic intoxication from well water in the United States. N Engl J Med 1973; 288: 828-830.
15. Guha Mazumder DN, Das-Gupta J, Chakraborty AK, et al. Environmental pollution and chronic arsenicosis in south Calcutta. Bull World Health Organ 1992; 70: 481-485.
16. Tsuda T, Nagira T, Yamamoto E, et al. Malignant neoplasms among residents who drank water contaminated by arsenic from a King's Yellow factory. Sangyo Ika Diagaku Zasshi 1989; 11: 289-301.
17. Tsuda T, Babazono A, Yamamoto E, et al. Ingested arsenic and internal cancer: historical cohort study followed 33 years. Am J Epidemiol 1995; 141: 198-219.
18. Tsuda T, Nagira T, Yamamoto M, et al. An epidemiologic study on cancer in certified arsenic poisoning patients in Toroku. Ind Health 1990; 28: 53-62.
19. Schwartz RA. Reichenstein disease. Int J Dermatol 1991; 30: 304-305.
20. Jaafar R, Omar I, Jidon AJ, et al. Skin cancer caused by chronic arsenical poisoning - a report of three cases. Med J Malaysia 1993; 98: 86-92.
21. Hill AB, Faning EL. Studies on the incidence of cancer and other causes among workers at a metal refinery. Int J Cancer 1976; 17: 310-317.
22. Welch K, Haggins I, Oh M, et al. Arsenic exposure, smoking and respiratory cancer in copper smelter workers. Arch Environ Health 1982; 37: 325-335.
23. Enterline PE, March GM. Cancer among workers exposed to arsenic and other substances in a copper smelter. Am J Epidemiol 1982; 116: 895-911.
24. Birmingham DJ, Key MM, Holaday DA, et al. An outbreak of arsenical dermatosis in a mining community. Arch Dermatol 1965; 91: 457-464.
25. Perhagen G. Lung cancer mortality among men living near an arsenic-emitting smelter, Am J Epidemiol 1985; 122: 684-694.
26. Simonato L, Moulin JJ, Javeland B, et al. A retrospective mortality study of workers exposed to arsenic in a gold mine and refinery in France. Am J Ind Med 1994; 25: 625-633.
27. Maloney ME. Arsenic in dermatology. Derm Surg 1996; 22: 301-304.
28. Schwartz RA. Arsenic and the skin. Int J Dermatol 1997; 36: 241-250.
29. Piamphongsant T. Severe chronic arsenic poisoning: a clinical clue to an epidemiologic study. Bull Dept Med Serv 1988; 13: 279-281.
30. Shannon RL, Strayer DS. Arsenic-induced skin toxicity. Hum Toxicol 1989; 8: 99-104.
31. Piamphongsant T, Sivaroroskul P, Erpaibool P, et al. Environmental chronic arsenic poisoning. Correlation between clinical manifestation, and level of arsenic in hair and nail. Bull Dept Med Serv 1988; 14: 219-223.
32. Tseng WP, Chu HM, How SW, et al. Prevalence of skin cancer in an endemic area of chronic arsenism in Taiwan. J Natl Cancer Inst 1968; 40: 453-463.
33. Morton W, Starr G, Pohl D, et al. Skin cancer and water arsenic in Lane County, Oregon. Cancer 1976; 37; 2523-2532.
34. Harrington JM, Middaugh JP, Morse DL, et al. A survey of population exposed to high concentrations of arsenic in well water, Fairbanks, Alaska. Am J Epidemiol 1978; 108: 377-385.
35. Southwick JW, Western AE, Beck MM, et al. An epidemiological study of arsenic in drinking water in Millard County, Utah. In: Lederer WH, Fernterheim RJ, eds. Arsenic: Industrial, Biomedical, Environmental Perspectives. New York: Van Nostrand Rheinhold, 1983; 210-225.
36. Piamphongsant T, Udomnitikul P. Arsenic levels in hair and nail and samples of normal adolescents in Ampher Ronpiboon. Bull Dept Med Serv 1989; 14: 225-230.
37. Smith AH, Hopenhayn-Rich C, Bates MN, et al. Cancer risks from arsenic in drinking water. Environ Health Perspect 1992; 97: 259-267.
38. Tsen WP, Chu HM, How SW, et al. Prevalence of skin cancer in an endemic area of chronic arsenism in Taiwan. J Natl Cancer Inst 1968; 40: 453-463.
39. Tsuda T, Babazono A, Ogawa T, et al. Inorganic arsenic: a dangerous enigma for mankind. Appl Organometal Chem 1992; 6: 309-322.
40. Lagerkvist B, Linderholm H, Nordberg GF. Vasospastic tendency and Raynaud's phenomenon in smelter workers exposed to arsenic. Environ Res 1980; 39: 465-474.
41. Engel RR, Hopenhayn-Rich C, Receveur O, et al. Vascular effects of chronic arsenic exposure: a review. Epidemiol Rev 1994; 16: 184-209.
42. Ch'i IC, Blackwell RQ. A controlled retrospective study on black foot disease, an endemic peripheral gangrene disease in Taiwan. Am J Epidemiol 1968; 88: 7-24.
43. Ko YC. A critic review of epidemiologic studies on black-foot disease. Sanyo-Ika Diagaku Zasshi 1986; 8: 339-353.
44. Lu FJ. Black foot disease: arsenic or humic acid. Lancet 1990; 336: 115-116.
45. Bates MN, Smith AH, Hopenhayn-Rich C. Arsenic ingestion and internal cancers: a review. Am J Epidemiol 1992; 135: 462-476.
46. Heyman A, Pfeiffer JB Jr, Willett RW, et al. Peripheral neuropathy caused by arsenical intoxication. A study of 41 cases with observations on the effects of BAL (2,3-dimercapto-propanal). N Engl J Med 1956; 254: 401-409.
47. Wagner SL, Maliner JS, Morton WE, et al. Skin cancer and arsenical intoxication from well water. Arch Dermatol 1979; 115: 1205-1207.
48. Eunanontal W. Peripheral neuropathy from arsenic in water-table well. Bull Dept Med Serv 1989; 14: 315-320.
49. Kreiss K, Felman RG, Landrigan PJ, et al. Neurologic evaluation of a population exposed to arsenic in Alaskan well water. Arch Environ Health 1983; 38: 116-121.
50. Armstrong CW, Stroube RB, Rubio T, et al. Outbreak of fatal arsenic poisoning caused by contaminated drinking water. Arch Environ Health 1984; 39: 276-279.
51. Kasper ML, Schoenfield L, Storm RL, et al. Hepatic angiosarcoma and bronchioloalveolar carcinoma induced by Fowler's solution. JAMA 1984; 252: 3407-3408.
52. Bates MN, Smith HH, Hopenhayn-Rich C. Arsenic ingestion and internal cancer: a review. Am J Epidemiol 1992; 135: 462-476.
53. Satterlee HS. The arsenic-poisoning epidemic of 1900. Its relation to lung cancer in 1960 - an exercise in retrospective epidemiology. N Engl J Med 1960; 263: 676-684.
54. Enterline PE, Day R, March GM. Cancer related to exposure to arsenic at a copper smelter. Occup Environ Med 1995; 52: 28-31.
55. Mabuchi K, Lilienfeld AM. Lung cancer among pesticide workers exposed to inorganic arsenicals. Arch Environ Health 1979; 34: 312-319.
56. Robson AO, Jelliffe AM. Medicinal arsenic poisoning and lung cancer. Br Med J 1963; 5351: 207-209.
57. Chen CJ, Wang CJ. Ecological correlation between arsenic level in well water and age adjusted mortality from malignant neoplasm. Cancer Res 1996; 50: 5470-5474.
58. Chen CJ, Kuo TL, Wu MM. Arsenic and cancers. Lancet 1988; 1: 414-415.
59. Wu MM, Kuo TL, Huang YH, et al. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 1989; 130: 1123-1132.
60. Cuzick J, Sasieni P, Evans S. Ingested arsenic, keratosis and bladder cancer. Am J Epidemiol 1992; 136: 417-421.
61. Beckman G, Beckman L, Nordenson I. Chromosome aberration in workers exposed to arsenic. Environ Health Perspect 1977; 19: 145-146.
62. Burgdorf W, Kurvink K, Cervenka J. Elevated sister chromatid exchange rate in lymphocytes of subjects treated with arsenic. Hum Genet 1977; 36: 69-72.
63. Mitchell N, Stöhrer G. Mutagenesis originating in site-specific DNA damage. J Mol Biol 1986; 191: 177-180.
64. Stöhrer G. Arsenic opportunity for risk assessment. Arch Toxicol 1991; 65: 525-531.
65. Fahrig R. Genetic mode of action of cocarcinogens and tumor promoters in yeast and mice. Mol Gen Genet 1984; 194: 7-14.
66. 4-ethylthymidinein liver DNA of individuals with or without malignant tumors. Cancer Res 1989; 49: 93-97.
67. 3H mice. Ann Clin Lab Sci 1974; 4: 441-447.
68. Chen CJ, Wu MM, Lee SS, et al. Atherogenicity and carcinogenicity of high-arsenic artesian well water: multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 1988; 8: 452-460.
69. Lee TC, Tanaka N, Lamb PW, et al. Induction of gene amplification by arsenic. Science 1988; 248: 79-81.
70. Piamphongsant T, Erpaibool P, Sivaroroskul P. Treatment of severe chronic arsenic poisoning with combination of etretinate and BAL. Bull Dept Med Serv 1989; 18: 178-181.
71. Miki Y, Kawatsu T, Matsuda K, et al. Cutaneous and pulmonary cancers associated with Bowen's disease. J Am Acad Dermatol 1982; 6: 26-31.
72. Wall S. Survival and mortality pattern among Swedish smelter workers. Int J Epidemiol 1980; 9: 73-87.
73. Jackson R, Grainge JW. Arsenic and cancer. Can Med Assoc J 1975; 113: 396-401.
74. Bates MN, Smith AH, Cantor KP. Case control study of bladder cancer and arsenic in drinking water. Am J Epidemiol 1995; 141: 523-530.
75. Graham JH, Helwig EG. Bowen's disease and its relationship to systemic cancer. Arch Dermatol 1961; 83: 738-758.
76. Brownstein MH, Rabinowitz AD. The precursors of cutaneous squamous cell carcinoma. Int J Dermatol 1979; 18: 1-16.
77. Graham JH, Helwig EB. Cutaneous precancerous condition in man. National Cancer Institute Monograph 1963; 10: 323-333.
78. Graham JH. Selected precancerous skin and mucocutaneous lesions. In: Malkinson FD, ed. Neoplasms of Skin and Malignant Melanoma. Chicago: Year Book Medical Publishers, 1976: 69-121.
79. Williams M, Fordyce F, Paijitprapaporn A, et al. Arsenic contamination in surface drainage and ground water in part of the Southeast Asia tin belt, Nakorn Sri Thammarat Province, Southern Thailand. Environ Geol 1996; 27: 16-33.
80. Tannapai S, Piamphongsant T, Nakjang Y. Chronic environmental arsenism. Bull Dept Med Serv 1989; 14: 307-314.
81. Piamphongsant T, Erpaibool P, Sivaroroskul P. Treatment of chronic arsenic poisoning: comparative study between penicillamine and BAL. Bull Dept Med Serv 1989; 18: 88-91.
82. Cullen NM, Wolf LR, St Clair D. Pediatric arsenic ingestion. Am J Emerg Med 1995; 13: 432-435.
83. Moore DF, O'Callaghan CA, Berlyne G, et al. Acute arsenic poisoning: absence of polyneuropathy after treatment with 2,3-dimercaptopropane sulphonate. J Neurol Neurosurg Psychiatry 1994; 57: 1133-1135.
84. Boyd Vl, Herbell SW, O'Conner RJ, et al. 2,3-Dithioerythritol a possible new arsenic antidote. Chem Res Toxicol 1989; 2: 301-306.
85. Fournier L, Thomas G, Garnier P, et al. 2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Med Toxicol Adverse Drug Exp 1988; 3: 499-504.
86. Marlin DS, Willis SE, Cline DM. N-Acetylcysteine in the treatment of human arsenic poisoning. J Am Board Fam Pract 1990; 3: 253-296.
87. Sharma SC, Simpson NB. Treatment of arsenic keratotic with etretinate. Acta Derm Venereol (Stockh) 1980; 68: 449-452.
88. Thianprasit M. Chronic cutaneous arsenicism treated with aromatic retinoid. J Med Assoc Thai 1984; 67: 93-100.
89. Szeimies RM, Karrer S, Heine A, et al. Arsenic-induced skin tumors treated with topical photodynamic therapy after application of 5-aminolevulinic acid. Eur J Dermatol 1995; 5: 208-211.
90. Welch ML, Grabski WJ, McCollough ML. 5-Fluorouracil iontophoretic therapy for Bowen's disease. J Am Acad Dermatol 1997; 36: 956-958.